ATE253361T1 - Mittel zur gesteuerten freisetzung von paroxetin - Google Patents

Mittel zur gesteuerten freisetzung von paroxetin

Info

Publication number
ATE253361T1
ATE253361T1 AT96926388T AT96926388T ATE253361T1 AT E253361 T1 ATE253361 T1 AT E253361T1 AT 96926388 T AT96926388 T AT 96926388T AT 96926388 T AT96926388 T AT 96926388T AT E253361 T1 ATE253361 T1 AT E253361T1
Authority
AT
Austria
Prior art keywords
paroxetine
agents
controlled release
release
controlled
Prior art date
Application number
AT96926388T
Other languages
English (en)
Inventor
Graham S Leonard
David P Edler
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10777960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE253361(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE253361T1 publication Critical patent/ATE253361T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Hydrogenated Pyridines (AREA)
AT96926388T 1995-07-20 1996-07-19 Mittel zur gesteuerten freisetzung von paroxetin ATE253361T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9514842.5A GB9514842D0 (en) 1995-07-20 1995-07-20 Novel formulation
PCT/EP1996/003252 WO1997003670A1 (en) 1995-07-20 1996-07-19 Paroxetine controlled release compositions

Publications (1)

Publication Number Publication Date
ATE253361T1 true ATE253361T1 (de) 2003-11-15

Family

ID=10777960

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96926388T ATE253361T1 (de) 1995-07-20 1996-07-19 Mittel zur gesteuerten freisetzung von paroxetin

Country Status (40)

Country Link
EP (2) EP0839039B2 (de)
JP (2) JP3922392B2 (de)
KR (1) KR100468351B1 (de)
CN (2) CN1117567C (de)
AP (1) AP1052A (de)
AR (1) AR003463A1 (de)
AT (1) ATE253361T1 (de)
AU (1) AU6659196A (de)
BG (1) BG64076B1 (de)
BR (1) BR9609857A (de)
CA (2) CA2445678C (de)
CY (1) CY2408B1 (de)
CZ (1) CZ294110B6 (de)
DE (1) DE69630603T3 (de)
DK (1) DK0839039T4 (de)
DZ (1) DZ2074A1 (de)
EA (2) EA003508B1 (de)
EG (1) EG23934A (de)
ES (1) ES2208757T5 (de)
GB (1) GB9514842D0 (de)
HU (1) HU228853B1 (de)
IL (1) IL122940A0 (de)
MA (1) MA23942A1 (de)
MX (1) MX9800571A (de)
MY (1) MY141373A (de)
NO (1) NO315637B1 (de)
NZ (1) NZ315006A (de)
OA (1) OA10652A (de)
PE (1) PE16098A1 (de)
PL (1) PL184987B1 (de)
PT (1) PT839039E (de)
RO (1) RO119119B1 (de)
SI (1) SI0839039T2 (de)
SK (1) SK284117B6 (de)
TR (1) TR199800077T1 (de)
TW (1) TW464513B (de)
UA (1) UA68328C2 (de)
UY (3) UY24288A1 (de)
WO (1) WO1997003670A1 (de)
ZA (1) ZA966148B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
JP2002503248A (ja) 1997-06-10 2002-01-29 シントン・ベスローテン・フェンノートシャップ 4−フェニルピペリジン化合物
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
IL133080A0 (en) 1997-07-01 2001-03-19 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
GB9808479D0 (en) * 1998-04-22 1998-06-17 Smithkline Beecham Plc Method of treatment
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
US6139875A (en) * 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating
ATE311883T1 (de) 1999-03-12 2005-12-15 Aesica Pharmaceuticals Ltd Stabile pharmazeutische anwendungsform für paroxetin-anhydrat
ES2290027T3 (es) * 1999-05-20 2008-02-16 Elan Corporation, Plc Formulaciones multiparticuladas y de liberacion controlada de inhibidores selectivos de la recaptacion de serotonina.
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
AU5078700A (en) * 1999-06-22 2001-01-09 Smithkline Beecham Plc Novel composition
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
ES2162560B1 (es) * 1999-06-25 2002-07-16 Rodriguez Concepcion Pena Uso de fluoxetina, paroxetina y otros isrs para la fabricacion de medicamentos con el fin de aumentar la capacidad de abstenerse de substancias o actividades que crean dependencia.
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
WO2003013480A1 (en) * 2001-08-06 2003-02-20 Dr. Reddy's Laboratories Ltd. Improved enteric formulation of fluoxetin
GB2392385A (en) * 2002-09-02 2004-03-03 Cipla Ltd Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolidone
JP5547865B2 (ja) 2003-10-29 2014-07-16 ワイス・エルエルシー アプリンドルおよびその誘導体を含む持続放出型医薬組成物
WO2005079756A2 (en) * 2004-02-13 2005-09-01 Neuromolecular, Inc. Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
WO2005107716A1 (en) * 2004-03-25 2005-11-17 Cadila Healthcare Limited Controlled release paroxetine-containing tablets based on a core and a coating
JP5153629B2 (ja) * 2005-08-02 2013-02-27 ルピン・リミテッド 選択的セロトニン再取り込み阻害剤の新規の制御放出組成物
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
WO2007132344A2 (en) * 2006-05-09 2007-11-22 Aurobindo Pharma Limited Controlled release compositions of an antidepressant agent
KR100885029B1 (ko) 2007-02-07 2009-02-23 지엘팜텍 주식회사 경구투여용 서방성 삼중정제
WO2009006299A2 (en) * 2007-06-29 2009-01-08 Dr. Reddy's Laboratories Ltd. Multi-particulate systems
JP5647519B2 (ja) 2007-09-13 2014-12-24 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化カテコールおよびベンゾ[d][1,3]ジオキソールおよびその誘導体の合成
TW201010743A (en) * 2008-09-05 2010-03-16 Otsuka Pharma Co Ltd Pharmaceutical solid preparation
CA2769872A1 (en) * 2009-08-24 2011-03-03 H. Lundbeck A/S New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
CN103371982A (zh) * 2012-04-20 2013-10-30 王进京 盐酸帕罗西汀肠溶控释片新型处方组成及制备方法
JP2015522047A (ja) * 2012-07-09 2015-08-03 ユニリーバー・ナームローゼ・ベンノートシヤープ 光保護パーソナルケア組成物
CN103550182B (zh) * 2013-10-29 2015-04-08 吉林省东盟制药有限公司 一种肠溶缓释组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
MC2025A1 (fr) * 1988-04-20 1990-04-25 Asta Pharma Ag Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
JPH0436237A (ja) * 1990-06-01 1992-02-06 Taiho Yakuhin Kogyo Kk 抗腫瘍性複合製剤
ATE137404T1 (de) * 1990-08-21 1996-05-15 Theratech Inc Zusammensetzungen zur kontrollierten freigabe
JPH06502854A (ja) * 1990-11-24 1994-03-31 ビーチャム・グループ・パブリック・リミテッド・カンパニー 老年痴呆、過食症、片頭痛または食欲不振の治療用のパロキセチンの使用
HUT69390A (en) * 1991-05-07 1995-09-28 Dynagen Inc Controlled, sustained release delivery system for smoking cessation
JPH05139964A (ja) * 1991-11-14 1993-06-08 Takada Seiyaku Kk 塩酸メキシレチン腸溶性製剤
EP0654263B1 (de) * 1993-11-23 2002-01-23 Euro-Celtique S.A. Verfahren zur Herstellung einer Arzneizusammensetzung mit verzögerter Wirkstoffabgabe
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
EP0818990A1 (de) * 1995-04-03 1998-01-21 Abbott Laboratories Homogene mischungen aus niedrigschmelzenden arzneistoffen und additiven zur verzögerten wirkstoffeingabe

Also Published As

Publication number Publication date
CA2445678A1 (en) 1997-02-06
UA68328C2 (en) 2004-08-16
PL324553A1 (en) 1998-06-08
JP2006265258A (ja) 2006-10-05
SI0839039T2 (sl) 2007-10-31
EP0839039B1 (de) 2003-11-05
CA2227298A1 (en) 1997-02-06
RO119119B1 (ro) 2004-04-30
HUP9900299A2 (hu) 1999-09-28
HU228853B1 (en) 2013-06-28
DK0839039T4 (da) 2007-10-08
SK284117B6 (sk) 2004-09-08
CN1195986A (zh) 1998-10-14
ES2208757T3 (es) 2004-06-16
BG102259A (en) 1998-09-30
HUP9900299A3 (en) 1999-11-29
GB9514842D0 (en) 1995-09-20
EG23934A (en) 2008-01-14
CN1515257A (zh) 2004-07-28
PL184987B1 (pl) 2003-01-31
EA199800140A1 (ru) 1998-10-29
DZ2074A1 (fr) 2002-07-22
BG64076B1 (bg) 2003-12-31
PE16098A1 (es) 1998-04-16
TR199800077T1 (xx) 1998-05-21
KR19990029076A (ko) 1999-04-15
CY2408B1 (en) 2004-09-10
EA003508B1 (ru) 2003-06-26
MX9800571A (es) 1998-04-30
EP0839039B2 (de) 2007-06-06
AR003463A1 (es) 1998-08-05
WO1997003670A1 (en) 1997-02-06
TW464513B (en) 2001-11-21
EP1382337A1 (de) 2004-01-21
DE69630603D1 (de) 2003-12-11
CA2445678C (en) 2009-11-24
NO980240L (no) 1998-01-20
DK0839039T3 (da) 2004-03-08
IL122940A0 (en) 1998-08-16
AP9801177A0 (en) 1998-01-31
UY24436A1 (es) 2001-08-27
AU6659196A (en) 1997-02-18
NO980240D0 (no) 1998-01-19
DE69630603T3 (de) 2008-01-03
MA23942A1 (fr) 1997-04-01
UY24288A1 (es) 1997-01-16
ZA966148B (en) 1998-01-19
CN1117567C (zh) 2003-08-13
NZ315006A (en) 2000-01-28
JPH11509539A (ja) 1999-08-24
CA2227298C (en) 2003-12-09
UY26242A1 (es) 2001-01-31
NO315637B1 (no) 2003-10-06
KR100468351B1 (ko) 2005-03-16
CN1282456C (zh) 2006-11-01
BR9609857A (pt) 1999-03-16
CZ18398A3 (cs) 1998-06-17
HK1010494A1 (en) 1999-06-25
AP1052A (en) 2002-03-21
MY141373A (en) 2010-04-16
EA200100022A1 (ru) 2001-06-25
DE69630603T2 (de) 2004-09-23
EP0839039A1 (de) 1998-05-06
CZ294110B6 (cs) 2004-10-13
JP3922392B2 (ja) 2007-05-30
SI0839039T1 (en) 2004-04-30
PT839039E (pt) 2004-03-31
ES2208757T5 (es) 2007-12-16
SK5398A3 (en) 1998-07-08
EA003775B1 (ru) 2003-08-28
OA10652A (en) 2002-09-18

Similar Documents

Publication Publication Date Title
DE69630603D1 (de) Mittel zur gesteuerten freisetzung von paroxetin
DE69522843D1 (de) Knochenanker
DE69836304D1 (de) Vorrichtung zur Vermeidung von Vorhof-Fibrillation
DE69812681D1 (de) Unsubstituierte polydiallylaminen zur behandlung von hypercholesterolemia
DE69428978D1 (de) Parfümierungsverfahren von geweben
DE59509539D1 (de) Zwischenwirbel-implantat
FR2729291B1 (fr) Implant rachidien
DE69827424D1 (de) Vorrichtung zur gesteuerten thermischen Behandlung von Gewebe
ATE313953T1 (de) Mittel zur bekämpfung von pflanzenschädlingen
DE59608798D1 (de) Endoparasitizide mittel
DE59712720D1 (de) Vorrichtung für den gesteuerten Nothalt von Aufzügen
DE69830591D1 (de) HEILUNG VON BRUCHVERLETZUNGEN UNTER VERWENDUNG VON PTHrP ANALOGEN
DE69603089D1 (de) Zusammensetzung zur behandlung von mauerwerk
DK0880892T3 (da) Midler med reguleret frigivelse
EP0996433A4 (de) Behandlungsverfahren von lactosylceramidbedingten zuständen
DE69520235D1 (de) Schweisshemmende mittel
DE59500266D1 (de) Transdermales therapeutisches System zur Applikation von Naloxon
DE69721756D1 (de) Paroxetine zur behandlung von depression
NO982911D0 (no) FremgangsmÕte for behandling av depresjon
DE59600130D1 (de) Vorrichtung zur Versorgung von Knochenbrüchen
DE69834937D1 (de) Antibiotika zur behandlung von magengeschwuren
ATA167097A (de) Vorrichtung zur körperlichen ertüchtigung von personen
DE59607463D1 (de) Vorrichtung zur kontrolle von flächenmassen
ATE346840T1 (de) Aminoalkylphenol-derivate zur behandlung von depression und gedächtnis-funktionsstörung
DE69806062D1 (de) Kombinationstherapie zur behandlung von aids

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0839039

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 0839039

Country of ref document: EP